



Rescission of NC State Health Director's Standing Order Authorizing Intravenous Administration of Sotrovimab Monoclonal Antibodies

I hereby rescind the standing order authorizing Intravenous Administration of Sotrovimab Monoclonal Antibodies that was issued on January 31<sup>st</sup>, 2022. Due to the high prevalence of the Omicron BA.2 variant of SARS-CoV-2 virus for which sotrovimab is not an effective treatment, the use of sotrovimab is no longer authorized in any US state or territory.

The rescission of this standing order shall not impact any actions taken in reliance on this standing order prior to the date of rescission.

A handwritten signature in black ink that reads 'E. Cuervo Tilson'.

Approved by: \_\_\_\_\_

Elizabeth Cuervo Tilson, MD, MPH  
NPI: 1760540421

Date Signed: 4-06-22\_\_\_\_\_